From the Journals

Keratinocyte carcinoma added no VTE risk in cohort study


 

FROM JAMA FACIAL PLASTIC SURGERY

Keratinocyte carcinoma patients were not at increased risk of venous thromboembolism (VTE) compared with controls in a recent population-based study of more than 700,000 insurance claims, according to investigators.

That finding suggests that clinicians should more carefully consider use of prophylactic anticoagulation in patients with squamous or basal cell carcinoma, said Shannon F. Rudy, MD, of Stanford (Calif.) University, and her coinvestigators. The report was published in JAMA Facial Plastic Surgery.

“While chemoprophylaxis is important when treating patients with an increased risk of VTE, it is equally important that such agents are not administered inappropriately because they can lead to perioperative complications,” wrote Dr. Rudy and her coauthors.

In current practice, patients with keratinocyte carcinomas (i.e., squamous cell carcinoma or basal cell carcinoma) are routinely classified at higher risk of thromboembolic events because of their diagnosis. That subsequently impacts treatment decisions regarding perioperative anticoagulation, the investigators noted.

Their population-based, retrospective analysis was based on insurance claims made between Jan. 1, 2007, and Dec. 31, 2014. The investigators identified three cohorts: 417,839 keratinocyte carcinoma patients, 314,736 controls at average risk of VTE, and 7,671 individuals considered to be at high risk of VTE because of a prior diagnosis of acute myeloid leukemia or pancreatic cancer.

In the keratinocyte carcinoma cohort, investigators found VTE risk was lower compared with the high-risk cohort in univariable analysis, multivariable analysis, and after matching patient characteristics and risk factors (odds ratio, 0.52; 95% confidence interval, 0.35-0.78; P = .001).

Compared with the control cohort, the keratinocyte carcinoma cohort had a higher risk of VTE in univariable analysis; however, the risk was lower in multivariable analysis, and not statistically different when patient characteristics and risk factors were matched (OR, 0.95; 95% CI, 0.89-1.01; P = .08).

Pages

Recommended Reading

Cancer-related clinical pearls from pediatric dermatology
MDedge Hematology and Oncology
CO2 laser guided by confocal microscopy effectively treated superficial BCC
MDedge Hematology and Oncology
New cases of Merkel cell carcinoma increased 95% between 2000 and 2013
MDedge Hematology and Oncology
HIV infection linked to higher risk of non-melanoma skin cancer
MDedge Hematology and Oncology
FDA begins priority review of cemiplimab for advanced cutaneous squamous cell carcinoma
MDedge Hematology and Oncology
Novel, noninvasive skin cancer detection device shows promise
MDedge Hematology and Oncology
Treatment of basal cell carcinoma with 1064-nm Nd:YAG laser promising
MDedge Hematology and Oncology
Patidegib, the first topical hedgehog inhibitor, scores in Gorlin syndrome
MDedge Hematology and Oncology
Cemiplimab impresses in advanced CSCC
MDedge Hematology and Oncology
Spotlight on nonmelanoma skin cancer’s true burden
MDedge Hematology and Oncology